High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma

Hematology/Oncology Clinics of North America

Volumn 17, Issue 6, 2003, Pages 1475-1483

  Oyama, Yu ^a   Guitart, Joan ^a   Kuzel, Timothy M ^a   Burt, Richard K ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MELPHALAN; METHYLPREDNISOLONE; PLATINUM; PREDNISONE; PSORALEN; VINCRISTINE;

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DRUG MEGADOSE; ELECTRON BEAM; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; VISCERAL METASTASIS; WHOLE BODY RADIATION;

EID: 0345735911     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00114-X     Document Type: Review

References (24)

1. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1998;109(5):372-82.
2. Phllip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333(23):1540-5.
3. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316(24):1493-8.
4. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, et al. High-dose carmustine, etoposide and cisplatin and autologous bone marrow transplantation for relapsed or refractory lymphoma. J Clin Oncol 1992;10(11):1682-9.
5. Vose JM, Armitage JO, Bierman PJ, Weisenburger DD, Hutchins M, Dowling MD, et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 1989;87(3):285-8.
6. Gribben JG, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 1989;7(11):1621-9.
7. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Doyen C, Morel P, et al. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. Ann Oncol 1998;9(Suppl):S5-8.
8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibert JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335(2):91-7.
9. Barlogie B, Jagannath S, Vasole DH, Naucke S, Mattox S, Bracy D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89(3):789-93.
10. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact of survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Blood 2000;95(1):7-11.
11. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566-71.
12. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP, et al. Graft-versus-leukemia effect in T-cell and B-cell lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998;21(2):153-8.
13. IBMTR/ABMTR Newsletter 2002;9(1).
14. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991;7(2):133-7.
15. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, et al. T-cell depletion and autologous stem cell transplantation in the management of tumor stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001;114(3):624-31.
16. Ferra C, Servitje O, Petriz L, Estrach T, Marti R, Limon A, et al. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 1999;140(6):1188-9.
17. Sterling JC, Marcus R, Burrows NP, Roberts SO. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 1995;20(1):73-5.
18. Chen YC, Wang CH, Huang SC, Lee EF, Lin DT, Shen MC, et al. Autologous bone marrow transplantation after supralethal dose of total body irradiation in a case of mycosis fungoides. Taiwan Yi Xue Hui Za Zhi 1986;85(3):304-14.
19. Soligo D, Ibatici A, Betri E, Morandi P, Longhi E, Venegoni L, et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 2003;31:663-6.
20. Masood N, Russell KJ, Olerud JE, Sabath DE, Sale G, Doney KC, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002;47(1):140-5.
21. Molina A, Arber DA, Murata-Collins JL, Raubitschek A, Forman SJ, Nademanee A. Allogeneic hematopoietic stem cell transplantation (HSCT) induces clinical, molecular and cytogenetic remission in patients with refractory Sezary syndrome (SS) and Advanced mycosis fungoides (MF) [abstract]. Ann Oncol 2002;13(Suppl 2):134.
22. Molina A, Aber D, Murata-Collins JL, Bernal A, Raubititschek A, Forman SJ, et al. Clinical, cytogenetic and molecular remission after allogeneic hematopoietic stem cell transplantation (HSCT) for refractory Sezary syndrome and tumor-stage mycosis fungoides [abstract]. Blood 2001;98(Suppl 1):409a.
23. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor AE, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002;138(10):1359-65.
24. Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000;25(1):111-3.